Nava Therapeutics is building next-gen lipid nanoparticles to do exactly that — targeting T cells, the kidney, and beyond.
Proud to back the team as they emerge with $89M and head toward the clinic. 🧬
F-Prime
@FPrimeCapital
We create and invest in healthcare and technology companies that impact lives all over the world.
